When controlled substances are lost or stolen while in transit, the DEA must be notified without delay. You should call in the report to the DEA right away, and then submit a written report within a short window. The written report must be filed within three days and should include the shipment date and the name of the carrier used. Providing these details helps the DEA trace the shipment and coordinate a prompt investigation, while a fuller report can include additional information as needed.

The key idea is how refills are regulated for Schedule III and IV medications. These drugs can be refilled, but with two limits: you may have up to five refills in a six-month period, and the total amount dispensed (initial plus all refills) cannot exceed a 120-day supply. This combination ensures patient access while preventing long, uncontrolled continuation of therapy. In practice, the two limits interact. For example, if you start with a 30-day supply, you could add up to three more 30-day refills to stay at 120 days total (120 days equals four fills total, including the initial). Even though five refills are allowed by the time window, the 120-day cap would stop you from dispensing more than 120 days' worth in that six-month period. If the initial supply is longer, say 90 days, you would reach the 120-day cap with fewer refills. The essential point is that five refills within six months is the maximum, but you cannot exceed a total of 120 days of supply.

The main idea is that drugs with significant safety risks require comprehensive patient counseling that covers how to use the medication correctly, how to store it, why following the directions matters, and the specific precautions and warnings that apply. For Addyi, all of these elements are essential because the drug carries a real risk of severe hypotension and syncope, especially in the context of alcohol use or certain drug interactions, and it is regulated under a REMS program to ensure safe use. Explaining how to use it and how to store it ensures the patient can take the medication correctly and keep it safe, including any dosing schedule (such as taking it at a specific time, with or without meals, and storage conditions). Emphasizing the importance of complying with directions helps the patient understand that deviating from instructions can markedly increase risk. Detailing precautions and warnings covers who should not use the drug, important interactions (such as with alcohol and CYP3A4 inhibitors), and other safety considerations that affect daily life and monitoring. Because Addyi's safety profile requires adherence to specific safety measures, counseling must include all of these aspects to protect the patient and meet regulatory requirements.

Any change that affects who is in charge, the facility’s license, or its physical location triggers a mandatory PIC self-assessment within 30 days. When a new permit is issued, the pharmacy is effectively entering a new licensing situation, so the PIC must review and confirm knowledge of current laws and procedures. If there is a new PIC, it’s essential for the individual taking charge to complete the assessment to demonstrate competency in the responsibilities of the role. Moving the pharmacy to a new location also changes the operational environment, storage, dispensing processes, and regulatory requirements, so another self-assessment is needed to ensure all aspects are up to date. Because any of these events require the assessment, the correct choice is all of the above. Completing it promptly helps maintain compliance and patient safety and provides documentation for regulatory inspections.